Amarantus BioScience announced that the Food and Drug Administration (FDA) has granted Orphan Drug designation for eltoprazine in the treatment of Parkinson’s disease levodopa-induced dyskinesia (PD-LID).

In Febraury 2015, the Company announced positive data for eltoprazine from a Phase 2 initial proof-of-concept clinical study and published the results in the journal Brain. Two additional independent peer-reviewed scientific publications highlighted eltoprazine and its mechanism of action for the treatment of PD-LID.

RELATED: Efficacy of Physical Therapy for Parkinson’s Questioned in Study

Eltoprazine is a small molecule 5HT1A/1B partial agonist currently under investigation for the treatment of PD-LID, adult attention deficit hyperactivity disorder (ADHD), and Alzheimer’s aggression.

For more information visit